Please try another search
YTD | 3M | 1Y | 3Y | 5Y | 10Y | |
---|---|---|---|---|---|---|
Growth of 1000 | 1069 | 949 | 1069 | 1029 | 1428 | 2345 |
Fund Return | 6.85% | -5.12% | 6.85% | 0.97% | 7.38% | 8.9% |
Place in category | 448 | 735 | 448 | 236 | 93 | 60 |
% in Category | 48 | 75 | 48 | 37 | 20 | 17 |
Name | Rating | Total Assets | YTD% | 3Y% | 10Y% | |
---|---|---|---|---|---|---|
Danske Invest Japani Osake K | 1.53B | 10.50 | 9.28 | 8.29 | ||
Danske Invest Japani Osake T | 1.53B | 10.54 | 9.29 | 8.31 | ||
Danske Invest Kompassi 25 Inc | 1.43B | 7.21 | 0.08 | 2.83 | ||
Danske Invest Kompassi 25 Acc | 1.43B | 7.18 | 0.07 | 2.83 | ||
Danske Invest Kompassi 50 Acc | 915.99M | 10.75 | 1.61 | 4.37 |
Name | Rating | Total Assets | YTD% | 3Y% | 10Y% | |
---|---|---|---|---|---|---|
Danske Invest MediLife K | 527.89M | 6.85 | 0.95 | 8.90 | ||
Seligson Global Top 25 Pharmac B | 260.28M | -0.23 | 2.84 | 6.31 | ||
Seligson Co Global Top 25 Pharma A | 260.28M | -0.23 | 2.84 | 6.29 | ||
LahiTapiola Hyvinvointi A | 124.72M | 1.33 | -2.07 | 6.97 | ||
LahiTapiola Hyvinvointi B | 124.72M | 1.33 | -2.06 | 6.97 |
Name | ISIN | Weight % | Last | Change % | |
---|---|---|---|---|---|
Eli Lilly | US5324571083 | 9.80 | 870.37 | +3.35% | |
AbbVie | US00287Y1091 | 5.52 | 192.97 | +0.64% | |
UnitedHealth | US91324P1021 | 5.09 | 530.04 | -1.81% | |
Thermo Fisher Scientific | US8835561023 | 4.30 | 572.71 | -1.66% | |
Novo Nordisk ADR | US6701002056 | 3.75 | 87.17 | +1.68% |
Type | Daily | Weekly | Monthly |
---|---|---|---|
Moving Averages | Buy | Buy | Buy |
Technical Indicators | Strong Buy | Strong Buy | Strong Buy |
Summary | Strong Buy | Strong Buy | Strong Buy |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review